Cochrane · systematic review · CD012715

Antihistamines for motion sickness

Karrim, N, Byrne, R, Magula, N, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library

ENTAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
24
current version
GRADE rated
13
No studies
11
Included studies
NR
No studies 11 · 45.8%Ungraded 0 · 0%Very low 6 · 25%Low 6 · 25%Moderate 1 · 4.2%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Antihistamines versus placebo for motion sickness

Population: patients with motion sickness
8 questions
OutcomeEffectEvidenceStatus / GRADE
Proportion of susceptible participants who did not experience any motion sickness symptoms under natural conditions Assessed by: self‐reported questionnaires6,7
Antihistamines vs placebo
RR 1.81 [1.23, 2.66]3 studies · 240 participantsModerate
Downgraded: risk of bias, imprecision
Proportion of susceptible participants who did not experience any motion sickness symptoms under experimental conditions Assessed by: rotating chair
Antihistamines vs placebo
no estimate extracted2 studies · 62 participantsVery low
Downgraded: risk of bias, imprecision
Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms
Antihistamines vs placebo
no estimate extractedNRNo studies
Physiological measures: heart rate and core temperature
Antihistamines vs placebo
no estimate extractedNRNo studies
Physiological measures: gastric tachyarrhythmia10 Assessed by: electrogastrography
Antihistamines vs placebo
no estimate extracted1 study · 42 participantsLow
Downgraded: imprecision
Adverse effects: sedation Assessed by: adverse effect questionnaire (presence or absence given numerical values)
Antihistamines vs placebo
RR 1.51 [1.12, 2.02]2 studies · 190 participantsLow
Downgraded: risk of bias, imprecision
Adverse effects: impaired cognition Assessed by: adverse effect questionnaire (presence or absence given numerical values)
Antihistamines vs placebo
RR 0.89 [0.58, 1.38]2 studies · 190 participantsLow
Downgraded: risk of bias, imprecision
Adverse effects: blurred vision Assessed by: adverse effect questionnaire (presence or absence given numerical values)
Antihistamines vs placebo
RR 1.14 [0.53, 2.48]2 studies · 190 participantsLow
Downgraded: risk of bias, imprecision

Antihistamines versus scopolamine for motion sickness

Population: patients with motion sickness
7 questions
OutcomeEffectEvidenceStatus / GRADE
Proportion of susceptible participants who did not experience any motion sickness symptoms under natural conditions Assessed by: self‐reported questionnaires6,7
Antihistamines vs scopolamine
RR 0.89 [0.68, 1.16]2 studies · 71 participantsVery low
Downgraded: risk of bias, imprecision
Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms
Antihistamines vs scopolamine
no estimate extractedNRNo studies
Physiological measures: heart rate Assessed by: self‐measured (participant measured own pulse rate)
Antihistamines vs scopolamine
no estimate extracted1 study · 20 participantsVery low
Downgraded: risk of bias, imprecision
Physiological measures: core temperature and gastric tachyarrhythmia (electrogastrography)
Antihistamines vs scopolamine
no estimate extractedNRNo studies
Adverse effects: sedation Assessed by: self‐reported
Antihistamines vs scopolamine
RR 0.82 [0.07, 9.25]2 studies · 90 participantsVery low
Downgraded: risk of bias, imprecision, inconsistency
Adverse effects: impaired cognitive function
Antihistamines vs scopolamine
no estimate extractedNRNo studies
Adverse effects: blurred vision Assessed by: self‐reported
Antihistamines vs scopolamine
no estimate extracted1 study · 51 participantsVery low
Downgraded: risk of bias, imprecision

Antihistamines versus antiemetics for motion sickness

Population: patients with motion sickness
5 questions
OutcomeEffectEvidenceStatus / GRADE
Proportion of susceptible participants who did not experience any motion sickness symptoms under experimental conditions Assessed by: calculated based on head movements tolerated (rotating chair); MSAQ
Antihistamines vs antiemetics
no estimate extracted1 study · 42 participantsLow
Downgraded: imprecision
Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms
Antihistamines vs antiemetics
no estimate extractedNRNo studies
Physiological measures: heart rate and core temperature
Antihistamines vs antiemetics
no estimate extractedNRNo studies
Physiological measures: gastric tachyarrhythmia2 Assessed by: electrogastrography
Antihistamines vs antiemetics
no estimate extracted1 study · 42 participantsLow
Downgraded: imprecision
Adverse effects: impaired cognition and blurred vision
Antihistamines vs antiemetics
no estimate extractedNRNo studies

Antihistamines versus acupuncture for motion sickness

Population: patients with motion sickness
4 questions
OutcomeEffectEvidenceStatus / GRADE
Proportion of susceptible participants who did not experience any motion sickness symptoms under experimental conditions Assessed by: Graybiel motion sickness scale
Antihistamines vs acupuncture
RR 1.32 [1.12, 1.57]1 study · 100 participantsVery low
Downgraded: risk of bias, imprecision
Proportion of susceptible participants who experienced a reduction or resolution of existing motion sickness symptoms
Antihistamines vs acupuncture
no estimate extractedNRNo studies
Physiological measures: heart rate, core temperature and gastric tachyarrhythmia (electrogastrography)
Antihistamines vs acupuncture
no estimate extractedNRNo studies
Adverse effects: sedation, impaired cognitive function, blurred vision
Antihistamines vs acupuncture
no estimate extractedNRNo studies